Harrisvaccines

Harrisvaccines. It was a privately held biotechnology company specializing in the development and production of novel veterinary vaccines. Founded by a professor from Iowa State University, the company leveraged a unique, rapid-response technology platform to address emerging animal diseases. Its work was particularly significant in the fields of swine and poultry health, contributing to the security of the United States food supply.

History and development

The company was founded in 2006 by Dr. Hank Harris, a professor of microbiology at the Iowa State University College of Veterinary Medicine. Its inception was driven by the need for faster vaccine development in response to outbreaks of diseases like porcine reproductive and respiratory syndrome virus. Initial research and development were closely tied to the resources and intellectual environment of Iowa State University, a leading institution in agricultural science. The company's growth was supported by investments from entities like the Iowa Fund of Funds and strategic partnerships within the animal health industry, positioning it as an innovator in the Midwestern United States biotech sector.

Technology platform

Harrisvaccines' core innovation was its proprietary SirraVax platform, based on RNA particle technology. This platform utilized synthetic messenger RNA to instruct host cells to produce specific viral proteins, thereby eliciting a protective immune response. A key advantage was the platform's speed, as vaccines could be designed and produced within weeks of obtaining a pathogen's genetic sequence, without the need to culture the live virus. This approach was conceptually similar to the later mRNA vaccine technology used by Moderna and Pfizer for human medicine, but Harrisvaccines applied it years earlier within the veterinary field.

Product portfolio

The company's commercial portfolio primarily served the swine industry. Its lead product, Suvaxyn PCV, was a vaccine for porcine circovirus associated diseases. Another significant product was its vaccine for porcine epidemic diarrhea virus, a devastating disease that caused severe losses in North American swine herds in the early 2010s. The company also developed vaccines for infectious bursal disease in poultry and had investigational candidates for other pathogens affecting cattle and fish. These products were marketed primarily to veterinarians and livestock producers across the United States.

Clinical trials and regulatory status

Harrisvaccines' products underwent rigorous clinical trials to demonstrate safety and efficacy for licensure by the United States Department of Agriculture Center for Veterinary Biologics. The Suvaxyn PCV vaccine's approval was a significant milestone, involving field trials across multiple swine production sites. The company's rapid-response vaccine for porcine epidemic diarrhea virus was made available under a conditional license from the USDA, a regulatory pathway for addressing emergent animal health threats. Data from these trials were often presented at scientific conferences like the American Association of Swine Veterinarians annual meeting.

Corporate affairs and partnerships

In 2015, Harrisvaccines was acquired by Merck Animal Health, a division of the global pharmaceutical giant Merck & Co.. This acquisition provided Harrisvaccines with greater resources for research and development and an expanded global distribution network. Prior to the acquisition, the company had secured funding from venture capital firms and formed research collaborations with institutions like Iowa State University. Following the acquisition, its operations were integrated into the Merck Animal Health infrastructure, though its research facility remained in Ames, Iowa.

Scientific and public health impact

The company demonstrated the practical application of mRNA technology in vaccinology years before its widespread adoption in human medicine during the COVID-19 pandemic. By providing tools to combat fast-moving zoonotic disease threats and production diseases, Harrisvaccines contributed to food security and animal welfare. Its work helped stabilize agricultural industries against economic shocks from outbreaks, supporting the livestock sectors in Iowa and nationwide. The company's legacy persists within Merck Animal Health's pipeline, influencing ongoing vaccine development for both companion animal and food animal diseases. Category:Biotechnology companies of the United States Category:Animal health companies Category:Companies based in Iowa